| Product Unit Size | Cost | Quantity | Stock |
|---|
SNS-032 is a CDK inhibitor with selectivity for CDK2 and CDK7/9. In chronic lymphocytic leukemia cells, SNS-032 induces apoptosis in vitro. It is used in combination with AT-7519 to exhibit anticancer effects in cervical cancer, inhibiting cancer cell migration in vitro and inhibiting tumor growth in a human xenograft tumor model.
| Cas No. | 345627-80-7 |
|---|---|
| Purity | ≥99% |
| Formula | C17H24N4O2S2 |
| Formula Wt. | 380.53 |
| Chemical Name | N-[5-[(5-Tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide |
| IUPAC Name | N-[5-({[5-(2-Methyl-2-propanyl)-1,3-oxazol-2-yl]methyl}sulfanyl)-1,3-thiazol-2-yl]-4-piperidinecarboxamide |
| Synonym | BMS387032; BMS-387032; SNS 032 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Chen R., Wierda W., et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 113(10):4637-45 (2009). PMID: 19234140.
Kang M., Kim W., et al. Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS‑032, on cervical cancer. Int J Oncol. 53(2):703-712 (2018). PMID: 29901072.